NASDAQ:SNDX - Syndax Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$5.28 -0.12 (-2.22 %)
(As of 11/13/2018 02:49 PM ET)
Previous Close$5.40
Today's Range$5.28 - $5.55
52-Week Range$4.36 - $15.20
Volume5,350 shs
Average Volume411,081 shs
Market Capitalization$134.61 million
P/E Ratio-1.83
Dividend YieldN/A
Beta2.63

Headlines

Syndax Pharmaceuticals (NASDAQ SNDX) News Headlines

Source:
DateHeadline
Syndax Pharmaceuticals Inc (SNDX) to Post FY2018 Earnings of ($3.29) Per Share, Oppenheimer ForecastsSyndax Pharmaceuticals Inc (SNDX) to Post FY2018 Earnings of ($3.29) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - November 8 at 6:21 AM
FY2018 Earnings Estimate for Syndax Pharmaceuticals Inc Issued By B. Riley (SNDX)FY2018 Earnings Estimate for Syndax Pharmaceuticals Inc Issued By B. Riley (SNDX)
www.americanbankingnews.com - November 8 at 6:21 AM
Syndax Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call SlidesSyndax Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 7 at 4:46 PM
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2018 Results - Earnings Call TranscriptSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 6 at 9:05 AM
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue EstimatesSyndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 6 at 9:05 AM
Edited Transcript of SNDX earnings conference call or presentation 5-Nov-18 9:30pm GMTEdited Transcript of SNDX earnings conference call or presentation 5-Nov-18 9:30pm GMT
finance.yahoo.com - November 6 at 9:05 AM
Syndax Pharmaceuticals (SNDX) Releases  Earnings Results, Beats Expectations By $0.08 EPSSyndax Pharmaceuticals (SNDX) Releases Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - November 6 at 8:14 AM
Syndax Pharmaceuticals Inc (SNDX) Expected to Post Quarterly Sales of $380,000.00Syndax Pharmaceuticals Inc (SNDX) Expected to Post Quarterly Sales of $380,000.00
www.americanbankingnews.com - November 6 at 1:04 AM
Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business UpdateSyndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update
finance.yahoo.com - November 5 at 4:47 PM
Syndax Pharmaceuticals Inc (SNDX) Expected to Post Earnings of -$0.76 Per ShareSyndax Pharmaceuticals Inc (SNDX) Expected to Post Earnings of -$0.76 Per Share
www.americanbankingnews.com - November 4 at 10:16 PM
Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual MeetingSyndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 4:45 PM
FY2019 EPS Estimates for Syndax Pharmaceuticals Inc Increased by Analyst (SNDX)FY2019 EPS Estimates for Syndax Pharmaceuticals Inc Increased by Analyst (SNDX)
www.americanbankingnews.com - October 31 at 9:36 AM
Syndax Pharmaceuticals (SNDX) Scheduled to Post Quarterly Earnings on MondaySyndax Pharmaceuticals (SNDX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 12:28 PM
Brokers Offer Predictions for Syndax Pharmaceuticals Incs Q1 2020 Earnings (SNDX)Brokers Offer Predictions for Syndax Pharmaceuticals Inc's Q1 2020 Earnings (SNDX)
www.americanbankingnews.com - October 30 at 8:48 AM
Analyst Actions: Oppenheimer Slashes Syndax Pharmas Price Target to $13 from $29, Keeps at Outperform - Stock Slumps 9%Analyst Actions: Oppenheimer Slashes Syndax Pharma's Price Target to $13 from $29, Keeps at Outperform - Stock Slumps 9%
www.nasdaq.com - October 29 at 4:34 PM
Syndax Pharmaceuticals (SNDX) Downgraded by Morgan Stanley to "Equal Weight"Syndax Pharmaceuticals (SNDX) Downgraded by Morgan Stanley to "Equal Weight"
www.americanbankingnews.com - October 29 at 10:51 AM
Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018
finance.yahoo.com - October 29 at 8:55 AM
Syndax Pharma down 25% on negative outcome of entinostat studySyndax Pharma down 25% on negative outcome of entinostat study
seekingalpha.com - October 26 at 4:46 PM
Syndax Pharmaceuticals Breast Cancer Treatment Fails to Reach Primary Endpoint; Shares Slide 18% To Record LowSyndax Pharmaceuticals' Breast Cancer Treatment Fails to Reach Primary Endpoint; Shares Slide 18% To Record Low
www.nasdaq.com - October 26 at 4:46 PM
Syndax Pharmaceuticals (SNDX) Price Target Cut to $23.00Syndax Pharmaceuticals (SNDX) Price Target Cut to $23.00
www.americanbankingnews.com - October 26 at 2:07 PM
After-Hours Stock Movers 10/25: (MAT) (EXPE) (CMG) Higher; (SGYP) (AMZN) (GOOGL) Lower (more...)After-Hours Stock Movers 10/25: (MAT) (EXPE) (CMG) Higher; (SGYP) (AMZN) (GOOGL) Lower (more...)
www.streetinsider.com - October 26 at 9:15 AM
Syndax Pharmaceuticals (SNDX) Says Phase 3 Breast Cancer Trial E2112 Shows PFS not Statistically SignificantSyndax Pharmaceuticals (SNDX) Says Phase 3 Breast Cancer Trial E2112 Shows PFS not Statistically Significant
www.streetinsider.com - October 26 at 9:15 AM
Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung CancerSyndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer
finance.yahoo.com - October 25 at 4:44 PM
Q3 2018 EPS Estimates for Syndax Pharmaceuticals Inc Increased by Analyst (SNDX)Q3 2018 EPS Estimates for Syndax Pharmaceuticals Inc Increased by Analyst (SNDX)
www.americanbankingnews.com - October 24 at 7:20 AM
Syndax Pharmaceuticals Inc (SNDX) Given Average Recommendation of "Buy" by AnalystsSyndax Pharmaceuticals Inc (SNDX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 21 at 7:28 AM
Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants,Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants,
www.nasdaq.com - October 18 at 9:03 AM
Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive Networks, KalVista Pharmaceuticals, and Adtalem Global Education — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive Networks, KalVista Pharmaceuticals, and Adtalem Global Education — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - October 18 at 9:03 AM
Syndax to Present at the 2018 Cantor Global Healthcare ConferenceSyndax to Present at the 2018 Cantor Global Healthcare Conference
finance.yahoo.com - September 26 at 9:17 AM
Do Options Traders Know Something About Syndax (SNDX) Stock We Dont?Do Options Traders Know Something About Syndax (SNDX) Stock We Don't?
www.nasdaq.com - September 25 at 4:34 PM
Syndax Announces Changes to its Board of DirectorsSyndax Announces Changes to its Board of Directors
finance.yahoo.com - September 25 at 4:33 PM
Do Options Traders Know Something About Syndax (SNDX) Stock We Don't?Do Options Traders Know Something About Syndax (SNDX) Stock We Don't?
finance.yahoo.com - September 25 at 4:33 PM
Syndax Mid-Stage Entinostat/Keytruda Trial for Lung Cancer Fails to Meet Endpoint - Stock Slumps 13% After-HoursSyndax Mid-Stage Entinostat/Keytruda Trial for Lung Cancer Fails to Meet Endpoint - Stock Slumps 13% After-Hours
www.nasdaq.com - September 25 at 8:43 AM
Syndax Pharma down 12% after hours on updated mid-stage data on entinostat/pembrolizumab combo in lung cancerSyndax Pharma down 12% after hours on updated mid-stage data on entinostat/pembrolizumab combo in lung cancer
seekingalpha.com - September 25 at 8:43 AM
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung CancerSyndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
finance.yahoo.com - September 24 at 4:40 PM
Are Syndax Pharmaceuticals Inc’s (NASDAQ:SNDX) Interest Costs Too High?Are Syndax Pharmaceuticals Inc’s (NASDAQ:SNDX) Interest Costs Too High?
finance.yahoo.com - September 13 at 8:42 AM
Edited Transcript of SNDX earnings conference call or presentation 7-Aug-18 8:30pm GMTEdited Transcript of SNDX earnings conference call or presentation 7-Aug-18 8:30pm GMT
finance.yahoo.com - September 11 at 4:43 PM
Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung CancerSyndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer
finance.yahoo.com - September 6 at 8:59 AM
Syndax Announces Participation at Three Upcoming Investor ConferencesSyndax Announces Participation at Three Upcoming Investor Conferences
finance.yahoo.com - August 28 at 9:01 AM
Syndax: IOMachine Says Breast Cancer Trial Data Should Be A Major CatalystSyndax: IOMachine Says Breast Cancer Trial Data Should Be A Major Catalyst
seekingalpha.com - August 25 at 9:09 AM
Is the Options Market Predicting a Spike in Syndax (SNDX) Stock?Is the Options Market Predicting a Spike in Syndax (SNDX) Stock?
www.zacks.com - August 21 at 9:03 AM
Syndax Pharmaceuticals, Inc.s (SNDX) CEO Briggs Morrison on Q2 2018 Results - Earnings Call TranscriptSyndax Pharmaceuticals, Inc.'s (SNDX) CEO Briggs Morrison on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 8 at 9:06 AM
Syndax Pharmaceuticals (SNDX) Reports Q2 LossSyndax Pharmaceuticals (SNDX) Reports Q2 Loss
finance.yahoo.com - August 8 at 9:06 AM
Syndax: 2Q Earnings SnapshotSyndax: 2Q Earnings Snapshot
finance.yahoo.com - August 8 at 9:06 AM
The Growth of Stem Cell Applications are Contributing to the Cell Therapy Processing MarketThe Growth of Stem Cell Applications are Contributing to the Cell Therapy Processing Market
www.prnewswire.com - August 7 at 4:49 PM
Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business UpdateSyndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update
finance.yahoo.com - August 7 at 4:49 PM
Syndax to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018Syndax to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
finance.yahoo.com - July 31 at 9:13 AM
Global Ocular Cancer Drug Development Pipeline Review 2018: 35 Products in Active Development Featuring ...Global Ocular Cancer Drug Development Pipeline Review 2018: 35 Products in Active Development Featuring ...
www.prnewswire.com - June 12 at 8:57 AM
Mining ASCO 2018s Gold, Part 7: Digest This News And Get Valuable InformationMining ASCO 2018's Gold, Part 7: Digest This News And Get Valuable Information
seekingalpha.com - May 31 at 9:19 AM
Syndax Pharmaceuticals, Nektar to Study NKTR-214 in Patients with PD-1 Refractory MelanomaSyndax Pharmaceuticals, Nektar to Study NKTR-214 in Patients with PD-1 Refractory Melanoma
www.nasdaq.com - May 31 at 9:19 AM
Syndax and Nektar Therapeutics team up in study of doublet therapy for advanced melanomaSyndax and Nektar Therapeutics team up in study of doublet therapy for advanced melanoma
seekingalpha.com - May 31 at 9:19 AM
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel